Toby N Weingarten1, Ashley M Taccolini2, Samuel T Ahle2, Kelsey R Dietz2, Shaun S Dowd2, Igor Frank3, Stephen A Boorjian3, Prabin Thapa4, Andrew C Hanson4, Darrell R Schroeder4, Juraj Sprung5. 1. Department of Anesthesiology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. weingarten.toby@mayo.edu. 2. Department of Anesthesiology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. 3. Department of Urology, College of Medicine, Mayo Clinic, Rochester, MN, USA. 4. Health Science Research and Biomedical Statistics and Informatics, College of Medicine, Mayo Clinic, Rochester, MN, USA. 5. Department of Anesthesiology, College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. sprung.juraj@mayo.edu.
Abstract
PURPOSE: The immune system plays an important role in tumour progression. Systemic opioids are immunosuppressive; thus, theoretically they may promote tumour spread. Our primary aim was to test the hypothesis that general anesthesia (GA) with spinal analgesia (SA) in patients with bladder cancer undergoing radical cystectomy (RC) will both reduce systemic opioid use and improve oncological outcomes. Since blood transfusions also induce immunosuppression, a secondary aim was to evaluate the effect of perioperative transfusions on oncological outcomes. METHODS: One hundred ninety-five patients who underwent RC with GA+SA from 1998-2007 were matched 1:1 to controls who underwent surgery with GA only using propensity scoring and tumour characteristics known to be highly associated with oncological outcomes. Medical records were reviewed for use of opioids and transfusions. Outcomes were tumour recurrence, cancer-specific mortality, and all-cause mortality. Survival was estimated using the Kaplan-Meier method, and associations of anesthetic technique and transfusions with outcomes were analyzed using stratified multivariable proportional hazard regression. RESULTS: Systemic opioid use was reduced with GA+SA relative to GA (P < 0.001). There was no difference between groups with respect to all-cause mortality (hazard ratio [HR], 1.09; 95% confidence interval [CI], 0.77 to 1.53; P = 0.636), bladder cancer mortality (HR, 1.03; 95% CI, 0.66 to 1.61; P = 0.893), or cancer recurrence (HR, 1.32; 95% CI, 0.86 to 2.02; P = 0.205). Nevertheless, patients who were perioperatively transfused had an increased all-cause mortality (HR, 2.21; 95% CI, 1.11 to 4.40; P = 0.025), and cancer-specific mortality (HR, 2.61; 95% CI, 1.05 to 6.48; P = 0.039). CONCLUSIONS: In patients undergoing RC, the opioid-sparing effect with SA was not associated with improved oncological outcomes, while blood transfusion was associated with increased mortality.
PURPOSE: The immune system plays an important role in tumour progression. Systemic opioids are immunosuppressive; thus, theoretically they may promote tumour spread. Our primary aim was to test the hypothesis that general anesthesia (GA) with spinal analgesia (SA) in patients with bladder cancer undergoing radical cystectomy (RC) will both reduce systemic opioid use and improve oncological outcomes. Since blood transfusions also induce immunosuppression, a secondary aim was to evaluate the effect of perioperative transfusions on oncological outcomes. METHODS: One hundred ninety-five patients who underwent RC with GA+SA from 1998-2007 were matched 1:1 to controls who underwent surgery with GA only using propensity scoring and tumour characteristics known to be highly associated with oncological outcomes. Medical records were reviewed for use of opioids and transfusions. Outcomes were tumour recurrence, cancer-specific mortality, and all-cause mortality. Survival was estimated using the Kaplan-Meier method, and associations of anesthetic technique and transfusions with outcomes were analyzed using stratified multivariable proportional hazard regression. RESULTS: Systemic opioid use was reduced with GA+SA relative to GA (P < 0.001). There was no difference between groups with respect to all-cause mortality (hazard ratio [HR], 1.09; 95% confidence interval [CI], 0.77 to 1.53; P = 0.636), bladder cancer mortality (HR, 1.03; 95% CI, 0.66 to 1.61; P = 0.893), or cancer recurrence (HR, 1.32; 95% CI, 0.86 to 2.02; P = 0.205). Nevertheless, patients who were perioperatively transfused had an increased all-cause mortality (HR, 2.21; 95% CI, 1.11 to 4.40; P = 0.025), and cancer-specific mortality (HR, 2.61; 95% CI, 1.05 to 6.48; P = 0.039). CONCLUSIONS: In patients undergoing RC, the opioid-sparing effect with SA was not associated with improved oncological outcomes, while blood transfusion was associated with increased mortality.
Authors: R Christopher Doiron; Melanie Jaeger; Christopher M Booth; Xuejiao Wei; D Robert Siemens Journal: Can Urol Assoc J Date: 2016 Sep-Oct Impact factor: 1.862
Authors: Brady L Miller; E Jason Abel; Glenn Allen; Jessica R Schumacher; David Jarrard; Tracy Downs; Kyle A Richards Journal: Am J Clin Exp Urol Date: 2020-02-25
Authors: Hao Zhang; Kefang Guo; Xingfeng Sun; Yi Liu; Ziwen Zhong; Wenchang Zhou; Weian Zeng; Lu Wang; Juan P Cata; Wankun Chen; Changhong Miao Journal: Ann Transl Med Date: 2021-01